이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!

Ion Beam Applications 미래 성장

Future 기준 확인 5/6

Ion Beam Applications (는) 각각 연간 74.7% 및 12.1% 수익과 수익이 증가할 것으로 예상됩니다. EPS는 연간 75% 만큼 성장할 것으로 예상됩니다. 자기자본이익률은 3년 후 31% 로 예상됩니다.

주요 정보

74.7%

수익 성장률

75.0%

EPS 성장률

Medical Equipment 수익 성장	18.1%
매출 성장률	12.1%
향후 자기자본 수익률	31.0%
애널리스트 커버리지	Low
마지막 업데이트	27 May 2024

최근 미래 성장 업데이트

Recent updates

It's Unlikely That The CEO Of Ion Beam Applications SA (EBR:IBAB) Will See A Huge Pay Rise This Year

Jun 06

Further Upside For Ion Beam Applications SA (EBR:IBAB) Shares Could Introduce Price Risks After 29% Bounce

Mar 25

Is Ion Beam Applications (EBR:IBAB) Using Too Much Debt?

Nov 07

Ion Beam Applications (EBR:IBAB) Has Some Way To Go To Become A Multi-Bagger

Oct 05

Ion Beam Applications (EBR:IBAB) Is Investing Its Capital With Increasing Efficiency

Jan 31

Is Ion Beam Applications (EBR:IBAB) A Risky Investment?

Sep 28

Here's Why Shareholders May Want To Be Cautious With Increasing Ion Beam Applications SA's (EBR:IBAB) CEO Pay Packet

Jun 01

Ion Beam Applications' (EBR:IBAB) Returns On Capital Are Heading Higher

May 29

Does Ion Beam Applications SA (EBR:IBAB) Have A Place In Your Dividend Stock Portfolio?

Apr 20

Is Ion Beam Applications (EBR:IBAB) A Risky Investment?

Mar 30

Should You Use Ion Beam Applications' (EBR:IBAB) Statutory Earnings To Analyse It?

Feb 10

What Type Of Shareholders Make Up Ion Beam Applications SA's (EBR:IBAB) Share Registry?

Jan 06

Does This Valuation Of Ion Beam Applications SA (EBR:IBAB) Imply Investors Are Overpaying?

Dec 10

Ion Beam Applications' (EBR:IBAB) Shareholders Are Down 64% On Their Shares

Nov 17

Ion Beam Applications SA (EBR:IBAB) Has Fared Decently But Fundamentals Look Uncertain: What Lies Ahead For The Stock?

Aug 20

Estimating The Intrinsic Value Of Ion Beam Applications SA (EBR:IBAB)

Jul 21

수익 및 매출 성장 예측

ENXTBR:IBAB - 애널리스트의 미래 추정치 및 과거 재무 데이터 (EUR Millions )
날짜	수익	수익	잉여 현금 흐름	작전 현금	평균 애널리스트 수
12/31/2026	620	44	N/A	50	3
12/31/2025	574	31	N/A	24	3
12/31/2024	506	12	N/A	-7	3
12/31/2023	429	-9	-32	-20	N/A
9/30/2023	400	-14	-45	-33	N/A
6/30/2023	371	-19	-59	-47	N/A
3/31/2023	366	-7	-22	-13	N/A
12/31/2022	361	6	14	22	N/A
9/30/2022	349	5	54	60	N/A
6/30/2022	336	4	93	98	N/A
3/31/2022	324	4	87	93	N/A
12/31/2021	313	4	82	87	N/A
9/30/2021	326	23	83	87	N/A
6/30/2021	339	42	83	87	N/A
3/31/2021	326	37	90	94	N/A
12/31/2020	312	32	96	100	N/A
9/30/2020	288	16	N/A	N/A	N/A
6/30/2020	264	1	69	73	N/A
3/31/2020	273	4	56	61	N/A
12/31/2019	283	8	44	49	N/A
9/30/2019	325	5	N/A	N/A	N/A
6/30/2019	295	-2	-9	11	N/A
3/31/2019	276	-3	-23	-4	N/A
1/1/2019	257	-4	-37	-19	N/A
9/30/2018	229	-25	-53	-40	N/A
6/30/2018	175	-45	-68	-61	N/A
3/31/2018	206	-43	-64	-53	N/A
12/31/2017	236	-42	-60	-45	N/A
9/30/2017	311	-14	N/A	-30	N/A
6/30/2017	335	12	N/A	-15	N/A
3/31/2017	332	18	N/A	-16	N/A
12/31/2016	329	25	N/A	-17	N/A
9/30/2016	312	40	N/A	-1	N/A
6/30/2016	294	55	N/A	15	N/A
3/31/2016	282	58	N/A	30	N/A
1/1/2016	270	61	N/A	45	N/A
10/1/2015	257	46	N/A	31	N/A
6/30/2015	243	31	N/A	17	N/A
3/31/2015	232	26	N/A	16	N/A
12/31/2014	221	21	N/A	15	N/A
9/30/2014	217	9	N/A	31	N/A
6/30/2014	213	-2	N/A	47	N/A
3/31/2014	213	-3	N/A	27	N/A
12/31/2013	213	-4	N/A	7	N/A
9/30/2013	212	-3	N/A	4	N/A
6/30/2013	212	-2	N/A	2	N/A

애널리스트 미래 성장 예측

수입 대 저축률: IBAB 은 향후 3년 동안 수익을 낼 것으로 예상되며, 이는 절약률( 1.1% )보다 빠른 성장으로 간주됩니다.

수익 vs 시장: IBAB (는) 향후 3년 동안 평균 시장 성장보다 높은 수익을 올릴 것으로 예상됩니다.

고성장 수익: IBAB 향후 3년 내에 수익을 낼 것으로 예상됩니다.

수익 대 시장: IBAB 의 수익(연간 12.1% ) Belgian 시장( 6.2% 보다 빠르게 성장할 것으로 예상됩니다. 6.2% 연간).

고성장 수익: IBAB 의 수익(연간 12.1% )은 연간 20% 보다 느리게 증가할 것으로 예상됩니다.

주당 순이익 성장 예측

미래 자기자본 수익률

미래 ROE: IBAB 의 자본 수익률은 3년 내에 최고 수준이 될 것으로 예상됩니다. ( 31 %)

Ion Beam Applications 미래 성장

Future 기준 확인 5/6

주요 정보

최근 미래 성장 업데이트

Price target increased by 12% to €17.50

Consensus EPS estimates fall by 20%

Price target decreased by 18% to €18.00

Price target increased by 26% to €22.30

Price target increased to €19.25

Price target increased to €17.75

Recent updates

Dividend of €0.12 announced

It's Unlikely That The CEO Of Ion Beam Applications SA (EBR:IBAB) Will See A Huge Pay Rise This Year

Price target increased by 12% to €17.50

Full year 2023 earnings: EPS and revenues exceed analyst expectations

Further Upside For Ion Beam Applications SA (EBR:IBAB) Shares Could Introduce Price Risks After 29% Bounce

Full year 2023 earnings released

Ion Beam Applications SA to Report First Half, 2024 Results on Aug 29, 2024

Ion Beam Applications S.A., CMI Inc. and Life Molecular Imaging Announce Japanese Approval for the Reimbursement of Amyloid-Pet Diagnostic Neuraceq in Alzheimer's Disease

Consensus EPS estimates fall by 20%

Ion Beam Applications SA, Annual General Meeting, Jun 12, 2024

Is Ion Beam Applications (EBR:IBAB) Using Too Much Debt?

New minor risk - Share price stability

Ion Beam Applications S.A Plans Total System Restoration on its First-Ever Proton Therapy Installation

Price target decreased by 18% to €18.00

Insufficient new directors

Price target increased by 26% to €22.30

Full year 2022 earnings released

Ion Beam Applications SA to Report Q1, 2023 Results on May 18, 2023

Price target increased to €19.25

Ion Beam Applications (EBR:IBAB) Has Some Way To Go To Become A Multi-Bagger

First half 2022 earnings released: €0.059 loss per share (vs €0.066 loss in 1H 2021)

Ion Beam Applications SA Continues to Shape the Future of Proton Therapy At Estro 2022 Annual Congress

Ion Beam Applications SA (ENXTBR:IBAB) acquired Modus Medical Devices Inc.

Full year 2021 earnings: EPS exceeds analyst expectations

Price target increased to €17.75

Investor sentiment improved over the past week

Ion Beam Applications (EBR:IBAB) Is Investing Its Capital With Increasing Efficiency

IBA Launches Compact Low-Energy Cyclotron, Cyclone® KEY

First half 2021 earnings released: €0.066 loss per share (vs €0.41 loss in 1H 2020)

First half 2021 earnings released: €0.066 loss per share (vs €0.41 loss in 1H 2020)

First half 2021 earnings released: €0.066 loss per share (vs €0.41 loss in 1H 2020)

Is Ion Beam Applications (EBR:IBAB) A Risky Investment?

First half 2021 earnings released

Ion Beam Applications S.A. Announces Launch of a Large-Scale, Multi-Institutional, Randomized Controlled Clinical Trial

Price target increased to €15.00

Here's Why Shareholders May Want To Be Cautious With Increasing Ion Beam Applications SA's (EBR:IBAB) CEO Pay Packet

Ion Beam Applications' (EBR:IBAB) Returns On Capital Are Heading Higher

Does Ion Beam Applications SA (EBR:IBAB) Have A Place In Your Dividend Stock Portfolio?

Is Ion Beam Applications (EBR:IBAB) A Risky Investment?

Full year 2020 earnings released

IBA (Ion Beam Applications S.A. and NorthStar Medical Radioisotopes Expand Collaboration to Enable Global Availability of Diagnostic Radioisotope Technetium-99m (Tc-99m)

Ion Beam Applications SA Receives Down Payment from National Cancer Center Korea for A Second Proteus® System

Should You Use Ion Beam Applications' (EBR:IBAB) Statutory Earnings To Analyse It?

Price target raised to €12.60

Ion Beam Applications SA to Report Q3, 2021 Results on Nov 18, 2021

New 90-day high: €13.46

What Type Of Shareholders Make Up Ion Beam Applications SA's (EBR:IBAB) Share Registry?

Does This Valuation Of Ion Beam Applications SA (EBR:IBAB) Imply Investors Are Overpaying?

Ion Beam Applications' (EBR:IBAB) Shareholders Are Down 64% On Their Shares

New 90-day high: €11.96

New 90-day high: €11.68

Ion Beam Applications SA Signs Contract for the First End-To-End Rhodotron® Duo Solution for Multi-Purpose Irradiation in Taiwan

Ion Beam Applications SA Announces First Payment of EUR 20 Million Received for Strategic Licensing Deal in China

New 90-day high: €10.60

Ion Beam Applications SA to Report Fiscal Year 2020 Results on Mar 25, 2021

New 90-day low - €7.14

Ion Beam Applications SA (EBR:IBAB) Has Fared Decently But Fundamentals Look Uncertain: What Lies Ahead For The Stock?

New 90-day low - €7.30

Estimating The Intrinsic Value Of Ion Beam Applications SA (EBR:IBAB)

수익 및 매출 성장 예측

애널리스트 미래 성장 예측

주당 순이익 성장 예측

미래 자기자본 수익률

성장 기업 발견